A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma
Status:
Completed
Trial end date:
2021-10-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety profile and antitumor activity of
brentuximab vedotin administered in combination with nivolumab in patients with relapsed or
refractory Hodgkin lymphoma (HL)